Johnson & Johnson or Evotec SE: Who Invests More in Innovation?

Comparing R&D investments of Johnson & Johnson and Evotec SE.

__timestampEvotec SEJohnson & Johnson
Wednesday, January 1, 2014124040008494000000
Thursday, January 1, 2015183430009046000000
Friday, January 1, 2016181080009095000000
Sunday, January 1, 20171761400010554000000
Monday, January 1, 20183561900010775000000
Tuesday, January 1, 20195843200011355000000
Wednesday, January 1, 20206394500012340000000
Friday, January 1, 20217220000014277000000
Saturday, January 1, 20227664200014135000000
Sunday, January 1, 20235751900015048000000
Monday, January 1, 202417232000000
Loading chart...

Data in motion

Innovation Investment: A Tale of Two Giants

In the ever-evolving world of pharmaceuticals, innovation is the lifeblood that drives progress. Johnson & Johnson, a stalwart in the industry, has consistently outpaced Evotec SE in research and development (R&D) investments over the past decade. From 2014 to 2023, Johnson & Johnson's R&D expenses have surged by approximately 77%, peaking at $15 billion in 2023. In contrast, Evotec SE, a dynamic player in the biotech sector, has seen its R&D spending grow by over 360%, reaching nearly $77 million in 2022. Despite the stark difference in absolute numbers, Evotec's growth rate is impressive, reflecting its commitment to innovation. This comparison highlights the diverse strategies of a pharmaceutical giant and a biotech innovator, each striving to lead in their respective fields. As the industry continues to evolve, these investments will play a crucial role in shaping the future of healthcare.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025